OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models

MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it has received a mid six-figure re-order from a previously announced foundation model company developing advanced AI models for radiology. This order follows OneMedNet’s delivery of the first dataset under the customer agreement — based on the quality and completeness of that data. The customer is expanding on the multi-modal imaging data agreement, which was included as part of the more than $3 million in new bookings the Company announced on June 10, 2026, including engagements supporting foundation model development.

Under the agreement, OneMedNet delivers de-identified, multi-modal studies at scale, sourced directly from its healthcare provider partners. The re-order increases that data volume as the customer advances its model development. AI development in foundation radiology modeling depends on full-fidelity DICOM studies and images — complete imaging series with intact pixel data and acquisition metadata — delivered at scale. OneMedNet de-identifies each study at the source while preserving the diagnostic fidelity these models require, a standard that is difficult to meet with compressed or stripped-down secondary data.

“We have seen customers come back for repeat orders because of the speed with which we deliver, the quality of our full-fidelity data, and the fact that it comes directly from our healthcare provider partners — not intermediaries or secondary markets,” said Aaron Green, President & CEO of OneMedNet. “Nowhere does that matter more than in foundation AI. You cannot train a AI radiology model on degraded images or incomplete studies. We believe this order reflects a customer that has worked with our data at scale and determined it is the right foundation for the next stage of its model development.”

The studies delivered under the agreement span a diverse range of patient demographics, anatomical regions, scanner manufacturers, and acquisition protocols — characteristics essential for training generalizable, robust, and clinically reliable AI models. OneMedNet sources its data from a live network of more than 2,300 healthcare partner sites, applying de-identification at the source at the scale and standards required to train evolving AI foundation models.

Order highlights

• Mid six-figure re-order from previously announced foundation model company developing advanced AI models for radiology.
• Expands the multi-modal imaging data agreement included in the Company’s June 10, 2026 bookings announcement.
• Full-fidelity DICOM delivery: complete, de-identified studies and images with intact pixel data and acquisition metadata, preserving the diagnostic fidelity frontier model training requires.
• Scale and diversity: studies spanning patient demographics, anatomical regions, scanner manufacturers, and acquisition protocols, drawn from OneMedNet’s network of more than 2,300 healthcare partner sites.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to statements regarding the customer re-order, the benefits and capabilities of our products and the customer agreement, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NY Newscast takes no editorial responsibility for the same.